Dr. Matt Witkowski is an Assistant Professor at the University of Colorado Anschutz Medical Campus, where his research focuses on overcoming treatment resistance in high-risk B-cell acute lymphoblastic leukemia (B-ALL). His team aims to identify critical genetic and metabolic determinants driving B-ALL resistance to chemotherapy and chimeric antigen receptor-T cell therapy. During his PhD at the Walter and Eliza Hall Institute, under the guidance of Dr. Ross Dickins, Witkowski developed novel mouse models. These models were used to investigate how the tumor-suppressor IKAROS regulates transcriptional programs in T-cell Acute Lymphoblastic Leukemia (T-ALL) and BCR1::ABL+ B-ALL. His postdoctoral training at NYU School of Medicine with Dr. Iannis Aifantis involved researching the bone marrow microenvironment in B-ALL. This work led to the identification of leukemia-associated non-classical monocytes as a targetable component that can enhance therapeutic responses.